TG Therapeutics, Inc. (TGTX)Healthcare | Biotechnology | Morrisville, United States | NasdaqCM
36.22 USD
-0.74
(-2.002%) ⇩
(April 21, 2026, 3:05 p.m.
EDT)
Short-term: ★★★☆☆ | Long-term: ★★★★★ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:06 a.m. EDT
TGTX is in a high-conviction turnaround phase where the risk/reward profile has shifted dramatically to favor the long investor. With negative cash flow (favorable for growth), massive revenue growth (78%), and a $750M credit facility solving the liquidity headache, the stock is trading at a 'still reasonable' discount despite a 1.6 buy consensus. The short squeeze is actively building (13.5x short ratio) on a stock that is technically reclaiming 200DMA support. However, this momentum plays out in weeks; timing it for years requires patience through potential earnings volatility. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.051808 |
| AutoARIMA | 0.051808 |
| AutoTheta | 0.053372 |
| MSTL | 0.053541 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 70% |
| H-stat | 1.31 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.309 |
| Excess Kurtosis | -0.31 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 39.258 |
| Revenue per Share | 4.27 |
| Market Cap | 5,783,908,864 |
| Trailing P/E | 13.08 |
| Forward P/E | 15.24 |
| Beta | 1.76 |
| Profit Margins | 72.56% |
| Website | https://www.tgtherapeutics.com |
As of April 19, 2026, 12:06 a.m. EDT: Speculators are aggressively pricing in upside momentum for the upcoming month with high volume in ATM calls (April 17), suggesting a bullish breakout attempt over the $35 range. There is a 'call wall' at higher strikes ($40, $45) indicating potential targets in a rally. Conversely, heavy put open interest (OI) is concentrated deep in-the-money (OTM/15-28 range) with high IV, acting as a floor mechanism rather than active bearish pressure. The skew suggests 240/1 put writers are actively selling downside protection rather than buying it, reinforcing a source of income for short-term hedgers while equity buyers dominate flow.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.027112424 |
| Address1 | 3,020 Carrington Mill Blvd. |
| Address2 | Suite 475 |
| All Time High | 233.4375 |
| All Time Low | 0.95625 |
| Ask | 41.46 |
| Ask Size | 1 |
| Audit Risk | 9 |
| Average Analyst Rating | 1.7 - Buy |
| Average Daily Volume10 Day | 1,667,400 |
| Average Daily Volume3 Month | 1,843,206 |
| Average Volume | 1,843,206 |
| Average Volume10Days | 1,667,400 |
| Beta | 1.755 |
| Bid | 31.39 |
| Bid Size | 1 |
| Board Risk | 10 |
| Book Value | 4.522 |
| City | Morrisville |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 36.22 |
| Current Ratio | 4.102 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 37.24 |
| Day Low | 36.07 |
| Debt To Equity | 39.258 |
| Display Name | TG Therapeutics |
| Earnings Call Timestamp End | 1,772,112,600 |
| Earnings Call Timestamp Start | 1,772,112,600 |
| Earnings Growth | -0.061 |
| Earnings Quarterly Growth | -0.013 |
| Earnings Timestamp | 1,772,112,600 |
| Earnings Timestamp End | 1,777,897,800 |
| Earnings Timestamp Start | 1,777,897,800 |
| Ebitda | 123,383,000 |
| Ebitda Margins | 0.2002 |
| Enterprise To Ebitda | 45.148 |
| Enterprise To Revenue | 9.039 |
| Enterprise Value | 5,570,547,712 |
| Eps Current Year | 1.24324 |
| Eps Forward | 2.37595 |
| Eps Trailing Twelve Months | 2.77 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 212 554 4531 |
| Fifty Day Average | 30.9502 |
| Fifty Day Average Change | 5.269802 |
| Fifty Day Average Change Percent | 0.17026715 |
| Fifty Two Week Change Percent | -2.7112424 |
| Fifty Two Week High | 46.48 |
| Fifty Two Week High Change | -10.259998 |
| Fifty Two Week High Change Percent | -0.22074006 |
| Fifty Two Week Low | 25.28 |
| Fifty Two Week Low Change | 10.940001 |
| Fifty Two Week Low Change Percent | 0.43275318 |
| Fifty Two Week Range | 25.28 - 46.48 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,272,893,400,000 |
| Float Shares | 140,951,193 |
| Forward Eps | 2.37595 |
| Forward P E | 15.244429 |
| Free Cashflow | -43,978,876 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 399 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.83658 |
| Gross Profits | 515,572,992 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0719 |
| Held Percent Institutions | 0.66218 |
| Implied Shares Outstanding | 159,688,256 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,335,744,000 |
| Last Split Factor | 100:5625 |
| Long Business Summary | TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina. |
| Long Name | TG Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 5,783,908,864 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_143627354 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | 447,179,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 5,902,077,941 |
| Number Of Analyst Opinions | 7 |
| Open | 36.94 |
| Operating Cashflow | -24,772,000 |
| Operating Margins | 0.26221 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Peg Ratio | 1.61 |
| Phone | 212 554 4484 |
| Previous Close | 36.96 |
| Price Eps Current Year | 29.133554 |
| Price Hint | 2 |
| Price To Book | 8.00973 |
| Price To Sales Trailing12 Months | 9.38509 |
| Profit Margins | 0.7256 |
| Quick Ratio | 2.911 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.66667 |
| Region | US |
| Regular Market Change | -0.73999786 |
| Regular Market Change Percent | -2.0021589 |
| Regular Market Day High | 37.24 |
| Regular Market Day Low | 36.07 |
| Regular Market Day Range | 36.07 - 37.24 |
| Regular Market Open | 36.94 |
| Regular Market Previous Close | 36.96 |
| Regular Market Price | 36.22 |
| Regular Market Time | 1,776,798,308 |
| Regular Market Volume | 1,233,998 |
| Return On Assets | 0.09394 |
| Return On Equity | 1.02754 |
| Revenue Growth | 0.78 |
| Revenue Per Share | 4.27 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 159,688,256 |
| Shares Percent Shares Out | 0.18129998 |
| Shares Short | 28,943,524 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 27,523,903 |
| Short Name | TG Therapeutics, Inc. |
| Short Percent Of Float | 0.2366 |
| Short Ratio | 13.58 |
| Source Interval | 15 |
| State | NC |
| Symbol | TGTX |
| Target High Price | 60.0 |
| Target Low Price | 15.0 |
| Target Mean Price | 44.57143 |
| Target Median Price | 46.0 |
| Total Cash | 141,970,000 |
| Total Cash Per Share | 0.961 |
| Total Debt | 254,399,008 |
| Total Revenue | 616,286,976 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 2.77 |
| Trailing P E | 13.075812 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 31.95385 |
| Two Hundred Day Average Change | 4.2661514 |
| Two Hundred Day Average Change Percent | 0.13350978 |
| Type Disp | Equity |
| Volume | 1,233,998 |
| Website | https://www.tgtherapeutics.com |
| Zip | 27,560 |